CN116507320A - 与延长释放帕潘立酮可注射制剂相关的给药方案 - Google Patents

与延长释放帕潘立酮可注射制剂相关的给药方案 Download PDF

Info

Publication number
CN116507320A
CN116507320A CN202180080436.4A CN202180080436A CN116507320A CN 116507320 A CN116507320 A CN 116507320A CN 202180080436 A CN202180080436 A CN 202180080436A CN 116507320 A CN116507320 A CN 116507320A
Authority
CN
China
Prior art keywords
dose
paliperidone
paliperidone palmitate
pp6m
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180080436.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·戈帕尔
R·文卡塔苏布拉马尼安
H·特乔林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75888042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN116507320(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN116507320A publication Critical patent/CN116507320A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180080436.4A 2020-11-30 2021-05-07 与延长释放帕潘立酮可注射制剂相关的给药方案 Pending CN116507320A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063119382P 2020-11-30 2020-11-30
US63/119382 2020-11-30
PCT/EP2021/062144 WO2022111858A1 (en) 2020-11-30 2021-05-07 Dosing regimens associated with extended release paliperidone injectable formulations

Publications (1)

Publication Number Publication Date
CN116507320A true CN116507320A (zh) 2023-07-28

Family

ID=75888042

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180080436.4A Pending CN116507320A (zh) 2020-11-30 2021-05-07 与延长释放帕潘立酮可注射制剂相关的给药方案

Country Status (24)

Country Link
US (2) US11324751B1 (cg-RX-API-DMAC10.html)
EP (2) EP4025187B1 (cg-RX-API-DMAC10.html)
JP (2) JP7792409B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230116837A (cg-RX-API-DMAC10.html)
CN (1) CN116507320A (cg-RX-API-DMAC10.html)
AU (3) AU2021387679B2 (cg-RX-API-DMAC10.html)
CA (1) CA3203448A1 (cg-RX-API-DMAC10.html)
DK (1) DK4025187T3 (cg-RX-API-DMAC10.html)
ES (1) ES2974822T3 (cg-RX-API-DMAC10.html)
FI (1) FI4025187T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240086T1 (cg-RX-API-DMAC10.html)
HU (1) HUE065387T2 (cg-RX-API-DMAC10.html)
IL (1) IL303251A (cg-RX-API-DMAC10.html)
LT (1) LT4025187T (cg-RX-API-DMAC10.html)
MA (1) MA71365A (cg-RX-API-DMAC10.html)
MX (2) MX2023006370A (cg-RX-API-DMAC10.html)
PL (1) PL4025187T3 (cg-RX-API-DMAC10.html)
PT (1) PT4025187T (cg-RX-API-DMAC10.html)
RS (1) RS65133B1 (cg-RX-API-DMAC10.html)
SI (1) SI4025187T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400075T1 (cg-RX-API-DMAC10.html)
TW (2) TWI838623B (cg-RX-API-DMAC10.html)
WO (1) WO2022111858A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202400851B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4005555T3 (pl) 2020-11-30 2024-09-02 Janssen Pharmaceutica Nv Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu
SI4025187T1 (sl) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem
CN116528836A (zh) 2020-11-30 2023-08-01 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.
CA3230291A1 (en) * 2021-08-30 2023-03-09 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932327A (zh) * 2007-12-19 2010-12-29 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
CN102802631A (zh) * 2009-10-30 2012-11-28 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
CN103998026A (zh) * 2011-10-24 2014-08-20 恩都医药解决方案公司 可植入的药物递送组合物及其治疗方法
TW201642863A (zh) * 2015-04-07 2016-12-16 健生醫藥公司 用於長效可注射帕里皮酮(paliperidone)酯類遺漏劑量之投藥療程
US20200297729A1 (en) * 2017-10-27 2020-09-24 Shandong Luye Pharmaceutical Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CN101163702B (zh) 2005-04-25 2011-09-07 詹森药业有限公司 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
SI2529757T1 (sl) 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
WO2016157061A1 (en) * 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
CN114783258A (zh) 2015-06-19 2022-07-22 詹森药业有限公司 用于药物施用和混合的系统及用于所述系统的适当技术的训练
US20190183896A1 (en) * 2017-12-14 2019-06-20 SpecGx LLC One step milling process for preparing micronized paliperidone esters
SI4025187T1 (sl) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem
CN116528836A (zh) 2020-11-30 2023-08-01 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案
PL4005555T3 (pl) 2020-11-30 2024-09-02 Janssen Pharmaceutica Nv Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu
EP4025188B1 (en) 2020-11-30 2024-01-10 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.
CA3230291A1 (en) 2021-08-30 2023-03-09 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932327A (zh) * 2007-12-19 2010-12-29 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
CN102802631A (zh) * 2009-10-30 2012-11-28 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
CN103998026A (zh) * 2011-10-24 2014-08-20 恩都医药解决方案公司 可植入的药物递送组合物及其治疗方法
TW201642863A (zh) * 2015-04-07 2016-12-16 健生醫藥公司 用於長效可注射帕里皮酮(paliperidone)酯類遺漏劑量之投藥療程
US20200297729A1 (en) * 2017-10-27 2020-09-24 Shandong Luye Pharmaceutical Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension

Also Published As

Publication number Publication date
TW202440122A (zh) 2024-10-16
MX2023006370A (es) 2023-08-07
MA71365A (fr) 2025-04-30
RS65133B1 (sr) 2024-02-29
FI4025187T3 (fi) 2024-02-13
AU2024202306A1 (en) 2024-05-02
DK4025187T3 (da) 2024-03-04
EP4385564A2 (en) 2024-06-19
AU2026201895A1 (en) 2026-04-02
JP2023552149A (ja) 2023-12-14
IL303251A (en) 2023-07-01
PT4025187T (pt) 2024-02-28
CA3203448A1 (en) 2022-06-02
TWI838623B (zh) 2024-04-11
SI4025187T1 (sl) 2024-03-29
EP4025187A1 (en) 2022-07-13
AU2024202306B2 (en) 2026-01-15
US11324751B1 (en) 2022-05-10
KR20230116837A (ko) 2023-08-04
SMT202400075T1 (it) 2024-03-13
EP4385564A3 (en) 2024-10-09
US20230105276A1 (en) 2023-04-06
ES2974822T3 (es) 2024-07-01
PL4025187T3 (pl) 2024-04-29
TW202222318A (zh) 2022-06-16
HRP20240086T1 (hr) 2024-03-29
JP2026027249A (ja) 2026-02-18
WO2022111858A1 (en) 2022-06-02
ZA202400851B (en) 2025-04-30
AU2021387679A1 (en) 2023-07-20
JP7792409B2 (ja) 2025-12-25
EP4025187B1 (en) 2024-01-03
HUE065387T2 (hu) 2024-05-28
US20220168306A1 (en) 2022-06-02
LT4025187T (lt) 2024-02-12
US12208100B2 (en) 2025-01-28
MX2024013364A (es) 2024-12-06
AU2021387679B2 (en) 2024-01-18
TWI897289B (zh) 2025-09-11

Similar Documents

Publication Publication Date Title
CN116583270A (zh) 与延长释放帕潘立酮可注射制剂相关的给药方案
US12208100B2 (en) Dosing regimens associated with extended release paliperidone injectable formulations
CN116528836A (zh) 与延长释放帕潘立酮可注射制剂相关的给药方案
US12472184B2 (en) Dosing regimens associated with extended release paliperidone injectable formulations
HK40089508A (en) Dosing regimens associated with extended release paliperidone injectable formulations
HK40111350A (en) Dosing regimens associated with extended release paliperidone injectable formulations
HK40111349A (en) Dosing regimens associated with extended release paliperidone injectable formulations
HK40078120B (en) Dosing regimens associated with extended release paliperidone injectable formulations
HK40078120A (en) Dosing regimens associated with extended release paliperidone injectable formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination